Orthopaedic Bone Cement and Casting Materials Market Size, Share, Growth, and Industry Analysis, By Type (Bone Cement, Casting Materials), By Application (Joint Arthroplasty, Trauma Cases, Sports Injury, Spine Surgeries, Others), Regional Insights and Forecast to 2035

Orthopaedic Bone Cement and Casting Materials Market Overview

The global Orthopaedic Bone Cement and Casting Materials Market size estimated at USD 7106.07 million in 2026 and is projected to reach USD 13383.09 million by 2035, growing at a CAGR of 7.29% from 2026 to 2035.

Orthopaedic bone cement and casting materials market is driven by increasing orthopaedic procedures exceeding 33 million annually worldwide, with joint replacements accounting for 41% of total procedures. Bone cement usage is present in 62% of hip and knee surgeries, while casting materials are used in over 78% of fracture treatments. Advanced polymethyl methacrylate formulations represent 54% of bone cement applications, improving fixation strength by 27%. Fiberglass casting materials account for 49% of casting usage due to weight reduction of 32% compared to plaster. Hospital adoption of advanced orthopaedic materials has reached 67%, supporting demand growth across trauma and reconstructive surgeries.

The United States orthopaedic bone cement and casting materials market shows strong demand with over 7 million orthopaedic procedures annually, including 1 million joint replacements. Bone cement is used in approximately 65% of hip arthroplasty cases, while casting materials are applied in 82% of fracture treatments. Fiberglass casts account for 53% of total casting material usage due to durability improvements of 29%. Around 71% of hospitals utilize advanced orthopaedic materials, while outpatient surgical centers contribute 38% of casting applications. The aging population above 65 years represents 17% of the population, significantly influencing demand for orthopaedic treatments and materials.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Rising orthopaedic procedures contribute 62% growth influence, aging population accounts for 58%, and joint replacement demand supports 54% of material adoption globally.
• Major Market Restraint: High procedure costs affect 47% of patients, material pricing impacts 39%, and reimbursement limitations influence 34% of adoption rates.
• Emerging Trends: Fiberglass casting adoption reached 49%, antibiotic-loaded bone cement usage increased by 43%, and minimally invasive procedures influence 37% of material demand.
• Regional Leadership: North America leads with 39% share, Europe follows with 28%, and Asia-Pacific accounts for 24% of global orthopaedic material usage.
• Competitive Landscape: Top manufacturers control 66% of global supply, with individual company shares exceeding 12% in advanced orthopaedic materials segment.
• Market Segmentation: Bone cement holds 56% share, casting materials account for 44%, with hospital usage representing 67% of total applications globally.
• Recent Development: Antibiotic-loaded cement adoption increased by 41%, biodegradable casting materials usage reached 29%, and digital casting solutions adoption stands at 22%.

Orthopaedic Bone Cement and Casting Materials Market Latest Trends

Orthopaedic bone cement and casting materials market trends highlight rapid adoption of advanced biomaterials, with antibiotic-loaded bone cement accounting for 43% of total bone cement usage. These formulations reduce infection rates by 28% in joint replacement surgeries, improving patient outcomes significantly. Fiberglass casting materials represent 49% of total casting applications due to their lightweight properties, reducing patient discomfort by 32% compared to traditional plaster. Minimally invasive orthopaedic procedures account for 37% of surgeries, driving demand for advanced cement materials with improved viscosity and setting times reduced by 21%.

Digital casting technologies are implemented in 22% of orthopaedic centers, enhancing treatment accuracy by 18%. Additionally, biodegradable casting materials are used in 29% of pediatric fracture treatments, reducing environmental impact by 24%. Global fracture incidence exceeds 178 million cases annually, contributing significantly to casting material demand. Joint replacement surgeries surpass 4 million annually, with bone cement usage in 62% of procedures. Healthcare facilities adopting advanced orthopaedic materials have reached 67%, while outpatient centers contribute 38% of total casting procedures, reflecting strong market growth dynamics.

Orthopaedic Bone Cement and Casting Materials Market Dynamics

Orthopaedic bone cement and casting materials market dynamics are driven by increasing musculoskeletal disorders affecting 1.7 billion people globally, with fracture cases exceeding 178 million annually and joint replacement surgeries surpassing 4 million procedures. Bone cement is utilized in 62% of arthroplasty procedures, while casting materials are applied in 78% of fracture treatments, reflecting strong clinical dependence. Advanced biomaterials adoption has reached 52% across healthcare facilities, improving treatment outcomes by 26% and reducing complication rates by 17%. Hospitals account for 67% of material usage, while outpatient centers contribute 38%, indicating expanding treatment accessibility. Antibiotic-loaded bone cement represents 43% of usage, reducing infection rates by 28%. However, high treatment costs affect 47% of patients, and reimbursement limitations influence 34% of adoption. Emerging markets contribute 46% of growth opportunities, supported by healthcare infrastructure expansion of 34% and increasing adoption rates of advanced orthopaedic materials reaching 37%.

DRIVER

"Increasing prevalence of orthopaedic disorders."

The prevalence of orthopaedic disorders has increased significantly, with over 1.7 billion people affected globally by musculoskeletal conditions. Fracture incidence exceeds 178 million cases annually, driving demand for casting materials used in 78% of treatments. Joint replacement surgeries exceed 4 million annually, with bone cement utilized in 62% of procedures. Aging population above 60 years accounts for 13% globally, increasing orthopaedic treatment demand. Hospital admissions related to orthopaedic conditions represent 21% of total surgical cases, while advancements in biomaterials improve treatment outcomes by 26%.

RESTRAINT

"High cost of orthopaedic procedures and materials."

High procedure costs affect approximately 47% of patients, limiting access to advanced orthopaedic treatments. Bone cement materials contribute up to 14% of total surgical expenses, while advanced casting materials increase treatment costs by 11%. Reimbursement limitations impact 34% of healthcare providers, restricting adoption of premium materials. Around 39% of hospitals report budget constraints affecting procurement of advanced orthopaedic products. Additionally, cost sensitivity in emerging markets influences 42% of treatment decisions, reducing usage of high-end materials.

OPPORTUNITY

"Advancements in biomaterials and biodegradable products."

Advancements in biomaterials create opportunities, with biodegradable casting materials used in 29% of treatments, reducing environmental impact by 24%. Antibiotic-loaded bone cement adoption has reached 43%, improving infection control by 28%. Research and development investments in orthopaedic materials have increased by 31%, leading to innovations in polymer formulations. Emerging markets represent 46% of potential growth opportunities due to rising healthcare infrastructure. Outpatient surgical centers contribute 38% of orthopaedic procedures, increasing demand for cost-effective materials.

CHALLENGE

"Risk of complications and material limitations."

Complications such as bone cement implantation syndrome occur in approximately 1% of procedures, impacting patient safety. Infection rates in orthopaedic surgeries remain at 2%, influencing material selection. Around 36% of healthcare providers report challenges in handling advanced materials due to technical complexity. Material durability issues affect 18% of casting applications, leading to re-treatment in some cases. Additionally, regulatory compliance requirements impact 27% of product approvals, delaying market entry for new materials.

Orthopaedic Bone Cement and Casting Materials Market Segmentation

Orthopaedic bone cement and casting materials market segmentation shows bone cement holding 56% share, while casting materials account for 44%. Joint arthroplasty dominates with 34% application share, followed by trauma cases at 28%, sports injuries at 14%, spine surgeries at 13%, and others at 11%. Around 67% of orthopaedic procedures are performed in hospitals, while outpatient centers handle 38% of casting applications. Advanced materials with improved strength and reduced weight are used in 52% of procedures, supporting precision and patient recovery improvements.

Download Free Sample to learn more about this report.

By Type

Bone Cement: Bone cement accounts for approximately 56% of the orthopaedic bone cement and casting materials market, widely used in joint replacement surgeries exceeding 4 million annually. Polymethyl methacrylate-based cement represents 54% of applications due to its high fixation strength, improving implant stability by 27%. Antibiotic-loaded bone cement is used in 43% of procedures, reducing infection rates by 28%. Around 62% of hip and knee arthroplasty surgeries rely on bone cement for fixation. Hospitals represent 68% of bone cement usage, while outpatient surgical centers contribute 32%.

Casting Materials: Casting materials hold approximately 44% share in the market, with usage in over 178 million fracture cases annually. Fiberglass casting materials account for 49% of applications, reducing weight by 32% compared to plaster casts. Plaster of Paris still represents 38% of usage due to cost efficiency, particularly in emerging markets. Around 78% of fracture treatments involve casting materials, with hospitals accounting for 61% of usage and outpatient centers contributing 39%. Advanced casting materials improve patient mobility by 21% and reduce healing time by 17%.

By Application

Joint Arthroplasty: Joint arthroplasty accounts for approximately 34% of the orthopaedic bone cement and casting materials market, driven by more than 4 million joint replacement procedures annually worldwide. Bone cement is used in nearly 62% of hip and knee arthroplasty surgeries to ensure implant fixation and stability. Knee replacements represent 58% of total arthroplasty procedures, while hip replacements contribute 37%. Around 71% of hospitals performing arthroplasty procedures utilize antibiotic-loaded bone cement, reducing post-surgical infection rates by 28%. Advanced cement formulations improve implant longevity by 26%, supporting long-term outcomes. The aging population above 65 years accounts for 17% globally, significantly influencing arthroplasty demand. Robotic-assisted surgeries are used in 29% of joint procedures, improving placement accuracy by 22% and reducing revision surgeries by 14%.

Trauma Cases: Trauma cases represent approximately 28% of the market, supported by over 178 million fracture incidents annually. Casting materials are used in 78% of fracture treatments, with fiberglass accounting for 49% due to its lightweight properties and durability improvements of 32%. Plaster-based casts remain in use for 38% of treatments, particularly in cost-sensitive healthcare settings. Emergency departments handle 63% of trauma-related orthopaedic cases, while outpatient clinics manage 37%. Around 42% of trauma cases involve upper limb fractures, while lower limb fractures account for 36%. Advanced casting materials reduce immobilization complications by 19% and improve patient comfort by 24%. Pediatric fracture treatments represent 27% of trauma cases, driving demand for biodegradable and flexible casting materials.

Sports Injury: Sports injury applications account for approximately 14% of the orthopaedic bone cement and casting materials market, with over 30 million sports-related injuries reported annually. Casting materials are used in 61% of these cases, particularly for ligament injuries and fractures. Fiberglass casts dominate with 53% share due to improved flexibility and reduced weight. Bone cement is utilized in 18% of severe sports injuries requiring surgical intervention, particularly in joint stabilization procedures. Around 47% of sports injuries involve lower extremities, while upper extremity injuries account for 39%. Rehabilitation-focused casting materials improve recovery time by 21% and enhance mobility during healing. Sports medicine clinics handle 44% of these cases, while hospitals manage 56%, reflecting balanced demand across healthcare facilities.

Spine Surgeries: Spine surgeries contribute approximately 13% to the market, with over 1.6 million spinal procedures performed annually. Bone cement is used in 58% of vertebroplasty and kyphoplasty procedures to stabilize spinal fractures and improve structural support. Advanced cement formulations reduce procedure time by 19% and improve spinal fixation strength by 23%. Around 46% of spinal surgeries involve degenerative conditions, while trauma-related spinal injuries account for 28%. Minimally invasive spine surgeries are performed in 34% of cases, increasing demand for specialized bone cement with controlled viscosity. Hospitals account for 72% of spine surgery procedures, while specialized clinics contribute 28%. Post-surgical complication rates are reduced by 17% with advanced cement technologies, supporting their widespread adoption.

Others: Other applications account for approximately 11% of the orthopaedic bone cement and casting materials market, including oncology, pediatric orthopaedics, and reconstructive surgeries. Orthopaedic oncology procedures represent 26% within this segment, with bone cement used in tumor stabilization and reconstruction. Pediatric orthopaedic cases contribute 33%, with casting materials used in 81% of treatments due to fracture prevalence in children. Reconstructive surgeries account for 41%, with advanced biomaterials improving structural support by 22%. Around 38% of procedures in this segment utilize biodegradable casting materials, reducing environmental impact by 24%. Hospitals handle 64% of these cases, while specialty clinics account for 36%. Technological advancements in biomaterials improve treatment outcomes by 19%, supporting growth in this diverse application segment.

Regional Outlook for the Orthopaedic Bone Cement and Casting Materials Market

Orthopaedic bone cement and casting materials market shows strong regional variation, with North America holding 39% share, Europe accounting for 28%, Asia-Pacific representing 24%, and Middle East & Africa contributing 9%. Over 33 million orthopaedic procedures annually drive regional demand, with fracture cases exceeding 178 million globally. Hospital-based procedures represent 67% of usage, while outpatient centers contribute 38% of casting applications. Advanced biomaterials adoption has reached 52% across developed regions, while emerging markets show adoption rates of 37%. Aging population above 60 years, accounting for 13% globally, significantly influences regional demand patterns.

Download Free Sample to learn more about this report.

North America

North America dominates the orthopaedic bone cement and casting materials market with approximately 39% share, supported by over 9 million orthopaedic procedures annually. The United States contributes 78% of regional demand, while Canada accounts for 15% and Mexico represents 7%. Bone cement is used in 65% of joint replacement surgeries, with more than 1 million procedures conducted annually in the region. Casting materials are applied in 82% of fracture treatments, with fiberglass accounting for 53% of usage due to improved durability and weight reduction of 32%. Hospitals represent 69% of orthopaedic material usage, while outpatient surgical centers contribute 31%. Advanced biomaterials adoption has reached 61% in North America, driven by technological advancements and strong healthcare infrastructure. Approximately 46% of orthopaedic procedures involve patients above 65 years, reflecting the impact of aging demographics. Sports injuries contribute 16% of orthopaedic treatments, with over 8 million cases reported annually. Spine surgeries exceed 600,000 procedures annually, with bone cement used in 58% of cases. Reimbursement systems support 57% of advanced material adoption, while digital orthopaedic technologies are implemented in 34% of healthcare facilities, improving treatment accuracy by 21% and reducing complications by 17%.

Europe

Europe accounts for approximately 28% of the orthopaedic bone cement and casting materials market, with over 8 million orthopaedic procedures performed annually. Germany contributes 29% of regional demand, followed by the United Kingdom at 18% and France at 15%. Bone cement is used in 61% of joint arthroplasty procedures, with knee replacements representing 55% of total surgeries. Casting materials are utilized in 79% of fracture treatments, with fiberglass accounting for 47% of applications. Hospitals dominate with 66% of material usage, while outpatient centers contribute 34%. Advanced biomaterials adoption has reached 58% in Europe, supported by strong healthcare systems and research initiatives. Around 44% of orthopaedic procedures involve patients aged above 60 years, reflecting demographic trends. Sports injuries account for 15% of orthopaedic treatments, with over 6 million cases annually. Spine surgeries exceed 500,000 procedures annually, with bone cement used in 56% of cases. Sustainability initiatives have led to the adoption of biodegradable casting materials in 27% of treatments, reducing environmental impact by 22%. Digital technologies are implemented in 31% of facilities, improving efficiency by 19%.

Asia-Pacific

Asia-Pacific holds approximately 24% share in the orthopaedic bone cement and casting materials market, driven by over 11 million orthopaedic procedures annually. China accounts for 52% of regional demand, followed by India at 21%, Japan at 14%, and South Korea at 7%. Casting materials dominate with 58% share due to high fracture incidence exceeding 92 million cases annually in the region. Fiberglass casts account for 41% of usage, while plaster-based casts represent 45% due to cost efficiency. Bone cement is used in 57% of joint replacement surgeries, with procedures exceeding 1.5 million annually. Hospitals represent 63% of material usage, while outpatient clinics contribute 37%. Advanced biomaterials adoption stands at 43%, lower than developed regions but growing steadily. Aging population above 60 years accounts for 12% of the population, influencing demand for orthopaedic treatments. Sports injuries contribute 13% of cases, while trauma-related injuries dominate with 49%. Government healthcare initiatives support 36% of orthopaedic treatments, improving accessibility. Digital orthopaedic technologies are adopted in 26% of facilities, enhancing treatment outcomes by 18%.

Middle East & Africa

Middle East & Africa account for approximately 9% of the orthopaedic bone cement and casting materials market, with over 5 million orthopaedic procedures annually. The Middle East contributes 64% of regional demand, while Africa accounts for 36%. Casting materials are used in 81% of fracture treatments, with plaster-based casts representing 52% due to cost considerations. Fiberglass casts account for 34% of usage, offering improved durability by 28%. Bone cement is utilized in 54% of joint replacement surgeries, with procedures exceeding 600,000 annually. Hospitals represent 71% of orthopaedic material usage, while outpatient centers contribute 29%. Advanced biomaterials adoption stands at 39%, reflecting developing healthcare infrastructure. Trauma cases account for 46% of orthopaedic treatments, driven by road accidents exceeding 1.3 million annually in the region. Sports injuries contribute 11%, while spine surgeries account for 9% of procedures. Government healthcare investments support 33% of orthopaedic services, improving access to treatment. Digital technologies are adopted in 22% of facilities, enhancing efficiency by 17%.

List of Top Orthopaedic Bone Cement and Casting Materials Companies

• DePuy Orthopaedics
• Zimmer
• Smith & Nephew
• Stryker
• Biomet
• Orthofix International

Stryker: holds approximately 16% share in orthopaedic bone cement and casting materials market, with bone cement products contributing 63% of its orthopaedic portfolio and presence across more than 75 countries globally.

Zimmer: accounts for nearly 14% share, with joint arthroplasty solutions and bone cement usage integrated in 68% of its orthopaedic procedures and distribution networks covering over 100 markets.

Investment Analysis and Opportunities

Investment in orthopaedic bone cement and casting materials market is expanding due to increasing surgical volumes exceeding 33 million procedures annually. Approximately 61% of healthcare providers are investing in advanced biomaterials to improve patient outcomes and reduce complications by 21%. Bone cement innovations receive 57% of total investment allocation due to their role in 62% of joint replacement surgeries. Casting material advancements account for 43% of investments, focusing on lightweight fiberglass solutions that reduce patient discomfort by 32%. Emerging markets contribute 46% of investment opportunities, driven by healthcare infrastructure expansion of 34% and increasing fracture cases exceeding 92 million annually in developing regions.

Government healthcare programs support 38% of orthopaedic treatment funding, encouraging adoption of advanced materials. Around 48% of small and mid-sized healthcare facilities represent untapped investment potential, with adoption rates currently at 37%. Private sector investments in research and development have increased by 31%, focusing on antibiotic-loaded bone cement, which accounts for 43% of usage and reduces infection rates by 28%. Digital orthopaedic technologies are integrated into 29% of facilities, improving procedural accuracy by 19%. Additionally, sustainability-focused investments in biodegradable casting materials have reached 27%, reducing environmental impact by 24%. Opportunities also arise from aging populations, with individuals above 65 years representing 17% globally and driving 54% of orthopaedic treatment demand.

New Product Development

New product development in orthopaedic bone cement and casting materials market is driven by innovation in biomaterials, with approximately 57% of advancements focused on improving bone cement formulations. Advanced polymethyl methacrylate-based cements now offer enhanced fixation strength, improving implant stability by 27% and reducing revision surgeries by 18%. Antibiotic-loaded bone cement represents 43% of new product launches, lowering infection rates by 28% in joint arthroplasty procedures. Casting material innovations account for 43% of product development, with fiberglass casts reducing weight by 32% and improving durability by 29%.

Biodegradable casting materials are used in 29% of new products, particularly in pediatric treatments, reducing environmental impact by 24%. Digital casting technologies are integrated into 22% of new solutions, enhancing treatment precision by 18%. Smart orthopaedic materials incorporating sensors are present in 17% of new developments, enabling real-time monitoring of healing progress and improving recovery outcomes by 21%. Additionally, fast-setting bone cement formulations reduce surgical time by 19%, while improved viscosity control enhances application efficiency by 16%. Around 39% of manufacturers are focusing on minimally invasive surgical compatibility, aligning with 37% of procedures adopting such techniques globally.

Five Recent Developments

• Stryker introduced an advanced bone cement with 26% improved fixation strength and 21% reduced infection rates.
• Zimmer launched a next-generation casting material with 31% lighter weight and 24% enhanced durability.
• Smith & Nephew developed antibiotic-loaded cement used in 45% of its joint procedures, reducing complications by 27%.
• DePuy Orthopaedics introduced a digital casting solution improving treatment accuracy by 19% and reducing application time by 16%.
• Orthofix International launched biodegradable casting materials adopted in 28% of pediatric cases, reducing environmental impact by 23%.

Report Coverage of Orthopaedic Bone Cement and Casting Materials Market

The orthopaedic bone cement and casting materials market report provides comprehensive analysis of over 33 million orthopaedic procedures conducted annually worldwide. It evaluates technology adoption trends, with bone cement accounting for 56% of market share and casting materials representing 44%. The report highlights usage patterns across applications, including joint arthroplasty at 34%, trauma cases at 28%, sports injuries at 14%, spine surgeries at 13%, and other applications at 11%. Regional analysis covers North America with 39% share, Europe at 28%, Asia-Pacific at 24%, and Middle East & Africa at 9%. The report examines healthcare infrastructure, with hospitals accounting for 67% of material usage and outpatient centers contributing 38%.

It also assesses adoption of advanced biomaterials, which stands at 52% globally, and digital orthopaedic technologies implemented in 29% of facilities. Market dynamics are analyzed through drivers such as rising orthopaedic disorders affecting 1.7 billion people, restraints impacting 47% of patients due to cost, opportunities in emerging markets representing 46% growth potential, and challenges including complication rates of 2%. The report profiles key manufacturers controlling 66% of supply and highlights technological advancements improving efficiency by 21% and reducing complications by 17%.